- Persistent Systems partners with Nvidia to deploy AI solutions in Healthcare and Life Sciences
- The collaboration targets computational drug discovery using generative AI and advanced analytics
- HLS contributed nearly one-third of Persistent’s Rs 11,940 crore revenue in fiscal 2025
Persistent Systems Ltd. on Tuesday announced a tie-up with US chipmaker Nvidia Corp. for deployment of artificial intelligence-powered solutions in the fast-growing Healthcare and Life Sciences (HLS) segment. The collaboration will help HLS organisations advance computational drug discovery and improve research outcomes using generative AI and advanced analytics, a statement said.
The HLS segment, which contributed nearly a third of the total Rs 11,940 crore revenue in fiscal 2025, has been one of the fastest growing businesses for Persistent, driven by digital health initiatives and the growing demand for data-driven healthcare solutions, according to the FY25 annual report.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Pune-based Persistent will leverage Nvidia AI Enterprise for specialised Life Sciences R&D use cases, including preclinical research. "By enabling high-fidelity molecular simulation and virtual screening at scale, the collaboration applies AI to model and reason real-world biological and chemical behavior before it is realised in real-world wet laboratory environments," the company said.
Persistent will build and deploy production-grade Agentic AI applications for computational drug discovery using Nvidia tools. The application will deliver AI-driven molecular simulations that model the physical and chemical properties of molecules using large domain-specific models and create intelligent agents to streamline real-time drug discovery workflows. These agentic workflows enable research teams to translate digital simulations into wet laboratory experiments.
To deploy production-grade AI applications, Persistent will use Nvidia accelerated computes, servers, Nvidia AI Enterprise and Nvidia NIM microservices, the statement said.
"Through this collaboration, Persistent will also expand its AI and LLM engineering capabilities by leveraging NVIDIA AI infrastructure, training resources and certification programmes to deliver increasingly sophisticated data and AI platforms for clients," the company said.
Persistent Share Price Movement
Shares of Persistent Systems, a midcap IT stock, traded 2.6% lower as of 1:20 p.m., after the announcement, compared to a 0.5% advance in the benchmark Nifty 50. The stock is down 12% in the last one year and 28% on a year-to-date basis.
Out of the 43 analysts tracking Persistent Systems, 25 have a 'buy' rating on the stock, seven recommend a 'hold' and 11 suggest a 'sell', according to Bloomberg data. The average of 12-month analyst price targets is Rs 6,453, which implies a potential upside of 42%.
ALSO READ: Nvidia Makes Trillion-Dollar Forecast At Annual Product Expo
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.